BioLight will invest up to $3 million in Peripherex, which was founded on the invention of Professor Jeffrey Goldberg of Stanford University. BioLight Life Sciences Ltd. (TASE: BOLT) Investment agreement with privately owned US company Peripherex Inc. Peripherex develops solutions to diagnose and monitor peripheral vision impairment using a personal computer and a built-in camera, by monitoring eye movements. The test is designed to check for suspected glaucoma and other eye diseases that affect peripheral vision. Related Articles BioLight is investing $1 million in AEYE Health Peripherex based on an invention by Professor Jeffrey Goldberg, who serves as chair of the department of ophthalmology at the Byers Eye Institute at Stanford University, and in collaboration with the Israeli company UMOOVE. BioLight will invest $1 million in Peripherex, and has also been given the option to invest up to an additional $2 million until receipt of FDA approval for the Peripherex product, or eighteen months from initial closure, whichever is later. Professor Goldberg said: “The Peripherex team is excited to partner with Biolight to bring a product to market that allows simple objective measurement at home and in the clinic of peripheral vision. This program serves a major unmet need in eye care in glaucoma and other diseases, which is so essential to the treatment and preservation of patients’ vision. “. Yakov Mislin, CEO of BioLight, added: “We are pleased to lead the investment in Peripherex with the goal of providing an innovative, cost-effective and effective tool that will help prevent blindness in glaucoma patients. This investment is part of our strategy to focus on nearby companies for the commercial launch of products that Combining Digital Health and Ophthalmology” Published by Globes, Israel business news – en.globes.co.il – on July 28, 2021 © Copyright Globes Publisher Itonut (1983) Ltd. 2021 sight image: Shutterstock
0 Comments